Early Phase Biologic Development: Upstream and Downstream Processes Considerations
Summary: Biopharmaceutical products in development continue to increase in complexity, which effects how companies choose to express proteins and eventually, manufacture at clinical and commercial scale. In this webinar, co-organized with Medicon Valley Alliance, experts from Catalent Biologics and Sartorius discuss new cell line development methodologies, including new instrumentation, which are enabling complex programs to be performed more efficiently, as well as ways that perfusion tools are used to implement upstream process intensification for clinical and commercial programs.